Argo points to swelling disorder drug’s differentiated profile on Phase II success
Argo Biopharmaceutical has debuted new data from a Phase II study on its preventative therapy, BW-20805 in hereditary angioedema (HAE), …
Post
-
-
MRSA therapeutics market to reach $1.8bn across 7MM in 2034
The methicillin-resistant Staphylococcus aureus (MRSA) therapeutics market across the seven major pharmaceutical markets (7MM), comprising the US, 5EU (France, Germany, …
-
Climb Bio reports Phase I results for CLYM116 in IgA nephropathy
Climb Bio has reported positive initial findings from its ongoing Phase I trial of CLYM116, an anti-A Proliferation-Inducing Ligand (APRIL) …
-
Akeso and Summit’s ivonescimab meets OS goals in NSCLC
Akeso and Summit Therapeutics’ ivonescimab has shown further benefit in a first-line non-small cell lung cancer (NSCLC) Phase III study, …
-
Sensorion secures approval for HearConnex Phase I/II study in France
Sensorion has received authorisation from the French National Agency for Medicines and Health Products Safety (ANSM) for its clinical trial application …
-
Can CNS trial momentum convert into late-stage evidence?
The central nervous system (CNS) remains one of biopharma’s most strategically important therapy areas in 2026, but GlobalData’s clinical trials …
-
Ultragenyx mulls fate of rare disease programme on Phase III flop
Ultragenyx Pharmaceutical is deliberating the fate of its Angelman syndrome candidate, apazunersen, after the drug failed to show benefit in …
-
AbbVie could take BiTE of Tecvayli market share on Phase III MM win
AbbVie’s bispecific T-cell engager (BiTE) therapy, etentamig, has been shown to positively impact progression-free survival (PFS) in a Phase III …
-
Markel launches rare disease trial travel reimbursement scheme
Markel Insurance has launched a reimbursement scheme to help boost enrolment for international trials evaluating rare disease therapies. The enhancement is …
-
Treeline and Roche collaborate on TLN-121 combo trial for BCL
Treeline Biosciences has signed a clinical trial collaboration and supply agreement with Roche for a Phase I study assessing the …
-
Norroy receives China’s clearance for Phase III study of 177Lu-NYM032
Norroy Bioscience has received approval from the National Medical Products Administration (NMPA) to start a Phase III clinical trial in …
-
Teva’s mAb shows benefit in celiac disease study
Teva’s investigational anti-interleukin-15 monoclonal antibody (mAb) has met its primary endpoint in a Phase IIa trial in celiac disease. In the …
-
Narcolepsy market expected to reach $7.8bn across 7MM by 2035
The narcolepsy market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) is …
-
Alumis’ lupus drug heads to Phase III despite mid-stage miss
California-based biopharma company Alumis is taking its immunology candidate, envudeucitinib, to Phase III in a type of lupus, despite the …
-
Ocugen begins Phase III trial of OCU410 gene therapy for GA
Ocugen has initiated its global Phase III ArMaDa3 trial of OCU410, an investigational gene therapy for geographic atrophy (GA) secondary …
